Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype

Abstract

Methods and kits for determining whether a subject has or is predisposed to developing a disease which is associated with IL-1 polymorphisms and assays for identifying therapeutics for treating and/or preventing the development of these diseases are provided.

1 . A kit comprising a means for detecting one or more alleles selected from the group consisting of: allele 2 of the −511 marker of IL-B, allele 2 of +2018 of IL-1RN, allele 1 of the −511 marker of IL-1B, and allele 1 of +2018 of IL-1RN. 
     
     
         2 . A kit comprising a means for detecting at least two alleles selected from the group consisting of: allele 2 of the −511 marker of IL-1B, allele 2 of +2018 of IL-1RN, allele 1 of the −511 marker of IL-1B, and allele 1of +2018 of IL-1RN. 
     
     
         3 . The kit of  claim 1 , wherein said detecting means is used in a allele detection technique selected from the group consisting of:
 a) allele specific oligonucleotide hybridization;   b) size analysis;   c) sequencing;   d) hybridization;   e) 5′ nuclease digestion;   f) single-stranded conformation polymorphism;   g) allele specific hybridization;   h) primer specific extension; and   i) oligonucleotide ligation assay.   
     
     
         4 - 22 . (canceled) 
     
     
         23 . The kit of  claim 2 , wherein said detecting means is used in a allele detection technique selected from the group consisting of:
 a) allele specific oligonucleotide hybridization;   b) size analysis;   c) sequencing;   d) hybridization;   e) 5′ nuclease digestion;   f) single-stranded conformation polymorphism;   g) allele specific hybridization;   h) primer specific extension; and   i) oligonucleotide ligation assay.   
     
     
         24 . The kit of  claim 1 , wherein the detection means comprise oligonucleotides. 
     
     
         25 . The kit of  claim 24 , wherein the oligonucleotides are selected from the group consisting of polymerase chain reaction (PCR) primers, cDNAs, peptide nucleic acids (PNAs), restriction fragments and synthetic oligonucleotides. 
     
     
         26 . The kit of  claim 2 , wherein the detection means comprise oligonucleotides. 
     
     
         27 . The kit of  claim 26 , wherein the oligonucleotides are selected from the group consisting of polymerase chain reaction (PCR) primers, cDNAs, peptide nucleic acids (PNAs), restriction fragments and synthetic oligonucleotides.